Issue 2/2018
Content (21 Articles)
Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications
Chengliang Huang, Sitong Liu, Xiang Tong, Hong Fan
The natural agent 4-vinylphenol targets metastasis and stemness features in breast cancer stem-like cells
Hoi-Wing Leung, Chun-Hay Ko, Grace Gar-Lee Yue, Ingrid Herr, Clara Bik-San Lau
Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro
Jia-Feng Huang, Chun-Jie Wen, Guo-Zhi Zhao, Yi Dai, Ying Li, Lan-Xiang Wu, Hong-Hao Zhou
Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel
Matthew Scarpelli, Murtuza Rampurwala, Jens Eickhoff, Lakeesha Carmichael, Jennifer Heideman, Kimberly Binger, Jill Kolesar, Scott Perlman, Kim Harrow, Gary Dukart, Chris Liang, Robert Jeraj, Glenn Liu, Justine Yang Bruce
Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas
Bo Wang, Hao Yao, Xianbiao Xie, Junqiang Yin, Changye Zou, Gang Huang, Jingnan Shen
Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia
Chunlu Gao, Shuang Hu, Meihua Guo, Xin Hai, Jin Zhou
The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer
Al-Motassem Yousef, Mohammed Zawiah, Shorouq Al-Yacoub, Taha Kadi, Dua’ a Tantawi, Hanguin Al-Ramadhani
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
Junko Tahara, Kyoko Shimizu, Nao Otsuka, Junichi Akao, Yukiko Takayama, Katsutoshi Tokushige
Targeting ALK in pediatric RMS does not induce antitumor activity in vivo
Monika Wierdl, Lyudmila Tsurkan, Liying Chi, M. Jason Hatfield, Viktor Tollemar, Cori Bradley, Xiang Chen, Chunxu Qu, Philip M. Potter
Pulmonary administration of curcumin inhibits B16F10 melanoma lung metastasis and invasion in mice
Ken Shimada, Kentaro Ushijima, Chisato Suzuki, Michiko Horiguchi, Hitoshi Ando, Tomomi Akita, Mizuki Shimamura, Junki Fujii, Chikamasa Yamashita, Akio Fujimura
Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
Sakura Iizumi, Akihiko Shimomura, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Kan Yonemori, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E. Krop, Howard Burris, Angel Guerrero-Zotano, Carolyn D. Britten, Carlos Becerra, Jan Schellens, Donald A. Richards, Martin Schuler, Maysa Abu-Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, Jose Baselga
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure
Jan de Jong, Nahor Haddish-Berhane, Peter Hellemans, James Jiao, Juthamas Sukbuntherng, Daniele Ouellet
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Amikar Sehdev, Theodore Karrison, Yuanyuan Zha, Linda Janisch, Michelle Turcich, Ezra E. W. Cohen, Michael Maitland, Blase N. Polite, Thomas F. Gajewski, Ravi Salgia, Navin Pinto, Marc B. Bissonnette, Gini F. Fleming, Mark J. Ratain, Manish R. Sharma
Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients
Olivia Le Saux, Aurélie Bourmaud, Catherine Rioufol, Olivier Colomban, Jérôme Guitton, Vérane Schwiertz, Véronique Regnier, Benoit You, Florence Ranchon, Raymonde Maraval-Gaget, Pascal Girard, Franck Chauvin, Gilles Freyer, Michel Tod, Emilie Henin, Véronique Trillet-Lenoir
Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects
Inderjeet Singh, Akash Patel, Ronak Patel, Vinu Jose
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Colin D. Weekes, Lee S. Rosen, Anna Capasso, Kit Man Wong, Weilan Ye, Maria Anderson, Bruce McCall, Jill Fredrickson, Eric Wakshull, Steve Eppler, Quyen Shon-Nguyen, Rupal Desai, Mahrukh Huseni, Priti S. Hegde, Tony Pourmohamad, Ina Rhee, Alberto Bessudo
Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
John P. Fruehauf, Monica El-Masry, Katherine Osann, Basmina Parmakhtiar, Maki Yamamoto, James G. Jakowatz
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report
Fabienne Thomas, Gareth J. Veal, Souleiman El Balkhi, Thierry Lafont, Nicolas Picard, Laurence Brugières, Etienne Chatelut, Christophe Piguet
Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma
Jie Weng, Mengyun Tu, Bo Yang, Zhiyi Wang
Reply to: Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma
Kyoichi Kaira